Entrada Therapeutics CFO sells 1,733 shares for taxes

Entrada Therapeutics’ CFO had shares automatically sold to cover tax withholding tied to an equity award, leaving a six-figure direct holding.

Rhea-AI Filing Summary

Entrada Therapeutics, Inc. (TRDA) reported that its Chief Financial Officer, Kory James Wentworth, had 1,733 shares of common stock disposed of on September 2, 2026 to satisfy minimum statutory tax withholding obligations. The shares were automatically sold by the company under a mandatory sell-to-cover provision and were not a discretionary trade. After this tax-withholding transaction, the CFO directly held 117,277 shares of Entrada Therapeutics common stock.

Insider Trade Summary

Tax Withholding: 1,733 shares

Tax Withholding 1 txn

Insider WENTWORTH KORY JAMES

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock F1, F2	1,733	$7.1439	$12K

Holdings After Transaction: Common Stock — 117,277 shares (Direct)

Footnotes (2)

1. F1. Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares disposed for tax withholding: 1,733 shares Weighted average sale price: $7.1439 per share Sale price range: $6.97–$7.34 per share +1 more

4 metrics

Shares disposed for tax withholding 1,733 shares Common stock disposed on September 2, 2026 to cover tax withholding

Weighted average sale price $7.1439 per share Price for 1,733 shares sold under mandatory sell-to-cover

Sale price range $6.97–$7.34 per share Range of prices for multiple transactions included in the weighted average

Shares held after transaction 117,277 shares Directly owned Entrada Therapeutics common stock after September 2, 2026 transaction

Key Terms

sell-to-cover, weighted average price, statutory tax withholding obligations

3 terms

sell-to-cover financial

"pursuant to a mandatory sell-to-cover provision in the award agreement"

Sell-to-cover is when part of newly issued or exercised company stock is immediately sold to pay required taxes and fees, so the recipient keeps the remaining shares. For investors this matters because it reduces the number of shares insiders or employees actually hold after a grant, can create small, routine share sales that aren’t signal of cashing out, and slightly increases share supply on the market—like selling a portion of a paycheck to cover the tax bill.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

statutory tax withholding obligations financial

"required to cover minimum statutory tax withholding obligations."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TRDA report for its CFO on September 2, 2026?

TRDA reported that CFO Kory James Wentworth had 1,733 common shares disposed of on September 2, 2026 to cover minimum statutory tax withholding obligations under a mandatory sell-to-cover provision tied to an equity award.

Was the TRDA CFO’s September 2, 2026 transaction a discretionary sale?

No. The filing states the sale does not represent a discretionary trade by the CFO. Shares were automatically sold by the company pursuant to a mandatory sell-to-cover provision in the award agreement to satisfy tax withholding.

How many TRDA shares does the CFO hold after this Form 4 transaction?

After the reported tax-withholding disposition, CFO Kory James Wentworth directly holds 117,277 shares of Entrada Therapeutics common stock, as disclosed in the Form 4’s post-transaction ownership figure.

What price was reported for the TRDA shares sold to cover taxes?

The Form 4 reports a weighted average price of $7.1439 per share for the 1,733 shares. A footnote explains that the shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive.

Was the TRDA CFO’s tax-withholding transaction under a Rule 10b5-1 plan?

No. The Rule 10b5-1 checkbox is not marked as affirming a trading plan, and the footnotes describe a mandatory sell-to-cover mechanism rather than a discretionary Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 05:24 PM EDT Accepted by SEC EDGAR 09/03/2026 - 05:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WENTWORTH KORY JAMES

(Last) (First) (Middle)

C/O ENTRADA THERAPEUTICS, INC.

ONE DESIGN CENTER PLACE, SUITE 17-500

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Entrada Therapeutics, Inc. [ TRDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2026		F		1,733(1)	D	$7.1439(2)	117,277	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Jared Cohen, as Attorney-in-Fact	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)